SCHEDULE: Sands Capital Boosts Stake in Inhibikase Therapeutics

Sands Capital entities report a 14.7% beneficial ownership stake in Inhibikase Therapeutics, Inc., holding over 10.9 million shares.

Summary

• Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC, and Frank M. Sands collectively report beneficial ownership of 10,950,000 shares of Inhibikase Therapeutics, Inc. common stock.
• This represents 14.7% of the company's outstanding shares, based on 74,341,540 shares outstanding as of May 1, 2025.
• The reporting persons also hold Series A-1 and Series B-1 warrants to purchase an additional 5,475,000 and 10,068,120 shares, respectively.
• These warrants are not currently included in the reported beneficial ownership because they are not exercisable within 60 days of the filing date, and their exercise date is not yet determinable.
• The warrants include a beneficial ownership limitation, preventing exercise if it would result in ownership exceeding 19.99% of outstanding shares.

Sentiment

Score: 7

Explanation: The filing indicates a significant institutional investment by Sands Capital, a reputable firm, in Inhibikase Therapeutics. This large stake, coupled with additional warrants, suggests confidence in the company's long-term prospects, which is generally a positive signal for the market.

Positives

• A prominent institutional investor, Sands Capital, has taken a substantial 14.7% stake in Inhibikase Therapeutics, indicating potential confidence in the company's future prospects.
• The holding of additional warrants, though not currently exercisable, suggests a long-term interest and potential for increased investment in the company.

Negatives

• The significant number of warrants (over 15.5 million shares) held by Sands Capital are not currently exercisable within 60 days, meaning their full potential ownership is not immediately realized.

Risks

• The exercise of Series A-1 and Series B-1 warrants is contingent on specific SEC registration statement review timelines, making the exact exercise date currently indeterminable.
• Warrant exercise is capped at 19.99% beneficial ownership, limiting the extent to which Sands Capital can increase its stake through these instruments.

Future Outlook

Future increases in beneficial ownership by Sands Capital are possible upon the exercisability of their Series A-1 and Series B-1 warrants, contingent on SEC registration statement review processes.

Management Comments

• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

The investment by Sands Capital Life Sciences Pulse Fund II, L.P. in Inhibikase Therapeutics, Inc. reflects continued institutional interest in the biotechnology and pharmaceutical sectors, particularly in companies developing new therapies.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Increased institutional ownership may signal confidence and potentially stabilize the stock. Future warrant exercise could lead to dilution.
• Company Management: A significant institutional investor may increase scrutiny or influence on strategic decisions, although the filing states no intent to change control.

Next Steps

• Potential future exercise of Series A-1 and Series B-1 warrants by Sands Pulse Fund II, contingent on SEC registration statement review and the satisfaction of exercise conditions.

Key Dates

Recommendation

The filing indicates a significant institutional investment by Sands Capital in Inhibikase Therapeutics, representing a substantial 14.7% stake. While this signals confidence from a reputable investor, the Schedule 13G primarily discloses ownership and does not provide new operational or financial performance data to warrant a change in investment thesis. The presence of unexercised warrants suggests potential future commitment, but their exercise is contingent on regulatory processes. Therefore, maintaining a 'hold' position is appropriate until further operational or financial updates are available.

Keywords

Inhibikase Therapeutics, Sands Capital, Beneficial Ownership, SEC Filing, Biotechnology, Pharmaceuticals, Institutional Investment, Warrants